Physician profile
Michael Joseph Rish
NPI 1184616682
$3,322.62
in general payments reported to CMS, 2019-2025
30 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $244 · 2021: $577 · 2022: $396 · 2023: $524 · 2024: $389 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.42 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.76 | 2021-2025 | Ubrelvy, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $394.37 | 2019-2025 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $347.00 | 2019-2024 | Ajovy, Airduo Digihaler |
| Amgen INC. | $194.51 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $186.77 | 2020-2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $170.26 | 2019-2025 | Ozempic, Wegovy |
| Exact Sciences Corporation | $146.95 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $144.45 | 2019-2024 | |
| Glaxosmithkline, LLC. | $125.65 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Janssen Pharmaceuticals, INC | $122.82 | 2019-2021 | |
| Amarin Pharma, INC. | $115.71 | 2019-2022 | |
| Astellas Pharma US INC | $113.71 | 2019-2025 | Veozah |
| Axsome Therapeutics, INC. | $89.67 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $86.65 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $83.46 | 2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.91 | 2019-2020 | |
| Sanofi Pasteur INC. | $49.51 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $44.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.14 | 2019 | |
| Cranial Technologies, INC | $37.57 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $28.90 | 2019-2022 | |
| Corium, LLC | $22.92 | 2023 | Azstarys |
| Dexcom, INC. | $19.22 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $17.45 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.16 | 2019 | |
| Abbott Laboratories | $14.60 | 2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.99 | 2025 | Xifaxan |
| Phadia US INC. | $13.78 | 2021 | |
| Shire North American Group INC | $13.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.